Acinetobacter spp. bloodstream infection in hematological patients: a 10-year single-center study

Jia Li,Xiaomeng Feng,Jieru Wang,Qingsong Lin,Yizhou Zheng,Fengkui Zhang,Yingchang Mi,Xiaofan Zhu,Erlie Jiang,Zhijian Xiao,Jianxiang Wang,Sizhou Feng
DOI: https://doi.org/10.1186/s12879-023-08789-6
IF: 3.7
2023-01-01
BMC Infectious Diseases
Abstract:This study investigated the clinical and antimicrobial characteristics of Acinetobacter spp. bloodstream infection (BSI) in hematological patients. Risk factors for 30-day mortality and carbapenem-resistant Acinetobacter spp. (CRA) BSI acquisition were also identified. We reviewed forty hematological patients with Acinetobacter spp. BSI in a large Chinese blood disease hospital between 2013 and 2022. The remaining CRA isolates were subjected to whole-genome sequencing. The 30-day mortality rate was high at 35
What problem does this paper attempt to address?